Seelos Therapeutics, Inc. focuses on the development of products addressing needs in CNS disorders and rare diseases.

Seelos Therapeutics, Inc.

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

Mind Medicine (MindMed) Inc.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Metric
Company Name	Seelos Therapeutics, Inc.	Mind Medicine (MindMed) Inc.	Axsome Therapeutics, Inc.
Symbol		MNMD	AXSM
MSH ID	COM:SEELOSTHERAPEUTICS	CO:MINDMED	COM:AXSOME
Market	PRIVATE	STOCKS	STOCKS
Sector	Healthcare & Health Services	Healthcare	Healthcare
Industry	Pharmaceuticals	Biotechnology	Biotechnology
Country	US	CA	US
Stage		Post-IPO Equity	Post-IPO Equity
Employee Count		57	569
Website	seelostherapeutics.com	mindmed.co	axsome.com
LinkedIn
Founders

Metric
Market Cap	500.56M	3.92B
Enterprise Value
Monthly Web Traffic	17.91K	7.82K
Web Traffic Growth	-0.36	-0.74
Valuation
Raised Capital	75M	225M

Metric
Revenue			270.60M
Revenue (LTM)
Revenue (NTM)
Gross Profit			237.70M
EBITDA			-176.07M
Operating Income			-182.91M
Net Income			-239.24M
EPS			-5.27
Diluted EPS			-5.27
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			0.90
Operating Profit Margin			-0.86
EBITDA Margin			-0.65
Net Profit Margin			-0.88
Return on Equity			-1.12
Return on Assets			-0.41
Return on Capital Employed			-0.52

COM:SEELOSTHERAPEUTICS

Seelos Therapeutics, Inc.

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio			-20.81
P/B Ratio			16.01
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			16.65
EV Multiple			-11.57

Metric
Days Sales Outstanding			128.09
Days Payables Outstanding			506.28
Days Inventory Outstanding			229.29
Operating Cycle			383.54
Cash Conversion Cycle			-229.81
Asset Turnover			0.53

Metric
Operating Cash Flow			-145.08M
Free Cash Flow			-145.66M
Cash Flow to Debt			-0.81
Operating Cash Flow/Sales			-0.54
Free Cash Flow Yield			-0.03

Metric
Cash & Equivalents			386.19M
Accounts Receivable			-57.12M
Inventory			15.13M
Goodwill			12.04M
Debt to Capitalization			0.65
Debt to Assets			0.31
Current Ratio			4.46
Quick Ratio			3.46

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue			0.24
R&D to Revenue			0.37
SG&A to Revenue			0.44